RESUMEN
Data on the efficacy and tolerability of piribedil in Asians are scarce. Forty-nine Filipino PD patients with motor fluctuations were enrolled in an 8-week trial of piribedil of up to 150 mg/day. Mean improvement was 48% for the motor UPDRS scores (tremor showed greatest change), and 43% for activities of daily living. Mean daily levodopa dose decreased by 17%, and mean duration of effect of levodopa increased by 1.3 h (45%). Most common side effects were hallucinations (20%), dyskinesias (20%), dizziness (8%), and sleepiness (6%). This trial shows that piribedil is effective and well-tolerated by Asian patients with advanced PD at least with short-term use.
Asunto(s)
Pueblo Asiatico/genética , Levodopa/uso terapéutico , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/genética , Piribedil/uso terapéutico , Adulto , Anciano , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/fisiopatología , Estudios Prospectivos , Estadísticas no ParamétricasRESUMEN
We administered a culturally corrected University of Pennsylvania Smell Identification Test (ccUPSIT) consisting of 25 odor items to 20 patients with 'Lubag' or X-linked dystonia-parkinsonism and 20 control subjects matched by sex, age, educational background, smoking history, and geographical origin. The mean ccUPSIT score of Lubag patients (18 +/- 3.19) was statistically lower (P = 0.003) than controls (20.5 +/- 3.02). The smell scores did not correlate with phenotype, severity of dystonia, or duration of disease. Nine of 20 Lubag patients (45%) had ccUPSIT scores below the mean, with the lowest score being 11. This pilot study suggests that olfactory dysfunction may occur in Lubag patients.